HHS Public Access

Author manuscript

Neurobiol Aging. Author manuscript; available in PMC 2016 September 01.

Published in final edited form as:

Neurobiol Aging. 2015 September ; 36(9): 2501–2508. doi:10.1016/j.neurobiolaging.2015.05.021.

Stroke Risk Interacts with Alzheimer's Disease Biomarkers on Brain Aging Outcomes

Timothy J. Hohman, PhD[1,*], **Lauren Samuels, EdM**[1,2], **Dandan Liu, PhD**[1,2], **Katherine A. Gifford, PsyD**[1], **Shubhabrata Mukherjee, PhD**[3], **Elleena M. Benson, BA**[1], **Ty Abel, MD,PhD**[4], **Frederick L. Ruberg, MD**[5], **Angela L. Jefferson, PhD**[1], and **Alzheimer's Neuroimaging Initiative**[*]

[1]Vanderbilt Memory and Alzheimer's Center, Vanderbilt University School of Medicine, Nashville, TN

[2]Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN

[3]Department of Medicine, University of Washington, Seattle, WA

[4]Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN

[5]Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston MA

Abstract

Alzheimer's disease (AD) biomarkers and stroke risk factors independently predict cognitive impairment, likely through independent disease pathways. However, limited work has sought to describe the dynamic interplay between these important risk factors. This manuscript evaluated the interaction between stroke risk and AD biomarkers on hippocampal volume and cognitive performance. We first evaluated the interaction between stroke risk factors and AD biomarkers using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI, n=1202). We then extended our findings to an independent autopsy dataset from the National Alzheimer's Coordinating Center (NACC, n=1122) using measures of AD pathology. Stroke risk was quantified using the Framingham Stroke Risk Profile. In ADNI, stroke risk interacted with tau and amyloid levels in relation to baseline and longitudinal cognitive performance. Similarly, in NACC, stroke risk interacted with amyloid and tau positivity on cognitive performance. The effect of stroke risk factors on cognition was strongest in the absence of AD biomarkers or neuropathology,

[*]Address Correspondence to: Timothy J Hohman, PhD Vanderbilt Memory & Alzheimer's Center Vanderbilt University Medical Center 2525 West End Ave, 12th Floor, Suite 1200 Nashville, TN 37203 Phone: 615–343–8429 Timothy.J.Hohman@Vanderbilt.edu.

[*]Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Potential Conflicts of Interest NONE

providing additional evidence that AD biomarkers and stroke risk factors relate to cognition through independent pathways.

1. Introduction

Stroke risk factors, such as hypertension and cigarette smoking, have been associated with lower neuropsychological performance in elders with normal cognition and mild cognitive impairment (MCI; Brady et al., 2001) and in relation to incident Alzheimer's disease (AD; Kivipelto et al., 2002). While much AD work has focused on classifying “pure” AD in the absence of vascular disease (Jack et al., 2013; Jack et al., 2010), the autopsy literature has clearly demonstrated that the most common presentation of AD is a mixed pathology with contributions from amyloid-β (Aβ) plaques, tau neurofibrillary tangles, and cerebrovascular disease (Schneider, Arvanitakis, et al., 2007; Schneider & Bennett, 2010; Troncoso et al., 2008). The dynamic interplay among AD and cerebrovascular pathologies remains somewhat elusive, but their co-occurrence leaves open the possibility that risk factors for both may interact in conferring risk for neurodegeneration (e.g., hippocampal volume) and cognitive decline (e.g., neuropsychological performance).

Cerebrospinal fluid (CSF) biomarkers of AD include Aβ-42, total tau, and phosphorylated tau levels based on their strong associations with brain volume (de Souza et al., 2012; Fjell et al., 2010) neuropsychological impairment (Buerger et al., 2005; Jagust et al., 2009), and post-mortem AD pathology (Buerger et al., 2006). Similarly, stroke risk factors have shown strong associations with brain volume (Seshadri et al., 2004), neuropsychological impairment (Brady et al., 2001; Jefferson et al., *In Press*; Kivipelto et al., 2002), and cerebrovascular pathology (Wang et al., 2009; Wolf et al., 1991). In mouse models, there has been some evidence that certain stroke risk factors, such as smoking (Moreno-Gonzalez et al., 2013) and hypertension (Diaz-Ruiz et al., 2009; Gentile et al., 2009), actually exacerbate AD pathology. Thus, there may be differing effects of stroke risk factors on neurodegeneration depending on the presence or absence of AD biomarkers. Yet, despite the depth of research investigating AD biomarkers and stroke risk factors independently, less research has focused on evaluating whether these factors interact in relation to brain volume or neuropsychological performance.

The current study examines the interplay between stroke risk factors and CSF biomarkers in relation to cross-sectional and longitudinal measures of brain aging. First, in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset, we evaluate interactions between stroke risk factors and AD biomarkers in relation to cross-sectional and longitudinal hippocampal volume. Second, we test the same interactions in relation to cross-sectional and longitudinal neuropsychological performance. Finally, we replicate the observed interaction effects on neuropsychological performance in a second, independent cohort using the National Alzheimer's Coordinating Center (NACC) dataset. We could not analyze hippocampal volume in NACC because MRI data were not available for analysis, so replication analyses focus on cognitive performance. Our hypothesis was that the effect of stroke risk factors on brain aging outcomes would depend on AD biomarker levels whereby vascular risk would exacerbate brain aging in the presence of AD biomarkers.

2. Materials and Methods

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative launched in 2003 (ADNI; adni.loni.usc.edu). The initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and ADNI-2. To date these three protocols have recruited over 1500 adults, ages 55 to 90, excluding serious neurological disease other than AD, history of brain lesion or head trauma, and history of psychoactive medication use (for full inclusion/exclusion criteria see www.adni-info.org). Informed written consent was obtained from all participants at each site.

The replication sample was drawn from the National Alzheimer's Coordinating Center (NACC), which maintains a database of participant information collected from 34 past and present National Institute on Aging-funded Alzheimer's Disease Centers. In 2005, NACC implemented a standard protocol (i.e., Uniform Dataset, UDS), including clinical, medical, neurological, and neuropsychological data (Beekly et al., 2004). Analysis of both publically available databases was approved by our local Institutional Review Board.

2.1 Participants

We accessed publicly available data from ADNI on 6/1/2014. Participants were enrolled based on criteria outlined in the ADNI protocol (http://www.adniinfo.org/Scientists/AboutADNI.aspx). For the present analyses we included all participants who had CSF biomarker data, full vascular risk factor data needed to calculate a stroke risk score, and the outcome measure of interest. For the neuroimaging analyses, participants had to have a FreeSurfer measure of hippocampal volume derived from 1.5T MRI data, yielding 1082 participants. For cognitive analyses, participants had to have a composite measure of episodic memory and executive function, yielding 1202 participants with all measures of interest.

For the replication sample, we used neuropathology data because NACC does not have CSF biomarker data available for analysis. NACC participants between 55 and 90 years of age evaluated between 9/01/2005 and 9/29/2014 with neuropathology, neuropsychological, and stroke risk data were included, yielding 1122 participants.

2.2 Framingham Stroke Risk Profile (FSRP)

To assess systemic vascular health, we calculated FSRP at baseline in the ADNI dataset and at the last visit before death in the NACC dataset. FSRP assigns points for age, systolic blood pressure (accounting for anti-hypertensive treatment), history of diabetes, current cigarette smoking, prevalent cardiovascular disease (i.e., history of myocardial infarction, angina pectoris, coronary insufficiency, intermittent claudication, or heart failure), left ventricular hypertrophy, and history of atrial fibrillation (D'Agostino et al., 1994). In this study, the FSRP calculation is modified because left ventricular hypertrophy information is not available in ADNI or in NACC. FSRP values range from 0 to 44 with higher values indicating more adverse risk of stroke.

2.3 CSF Biomarker Processing (ADNI) and Autopsy Measures of Neuropathology (NACC)

ADNI's CSF protocol, including the quantification of Aβ-42 and tau, has been outlined in detail elsewhere (Jagust et al., 2009; Shaw et al., 2011). For the present analyses, we compiled a dataset across the UPENN1 – UPENN5 data sources available for download on the ADNI site and used the first measure of total tau and Aβ-42 available for each subject. Biomarker levels were entered as continuous predictors in statistical models.

In the NACC dataset, we used the semi-quantitative CERAD neuritic plaque staging to classify participants as either “amyloid positive” or “amyloid negative”. Individuals with no plaques or sparse plaques were considered amyloid negative, and those with moderate or frequent plaques were considered amyloid positive. Similarly, we used the semi-quantitative BRAAK neurofibrillary tangle staging to identify participants as either “tau positive” or “tau negative.” BRAAK stages 0, I and II were considered “tau negative,” and BRAAK stages III–VI were considered “tau positive.”

2.4 Composite Neuropsychological Measurements

The ADNI neuropsychological protocol has been reported in detail, including calculation of composite measures of episodic memory and executive function (P. K. Crane et al., 2012; Gibbons et al., 2012). We leveraged both the memory (ADNI-MEM) and the executive function (ADNI-EF) scores in the present analyses. Briefly, a single factor model based on item level data from the Rey Auditory Verbal Learning Test, the AD Assessment Scale-Cognitive Subscale, the Mini-Mental State Examination, and the Logical Memory test were used in the calculation of the ADNI-MEM score. Item level data from the Trail Making Test (A and B), Digit Span Backwards, Digit Symbol, Animal Naming, Vegetable Naming, and the Clock Drawing Test were used in the calculation of the ADNI-EF score.

We used a well-validated psychometric approach to co-calibrate memory and executive functioning scores from the ADNI and NACC databases (Crane et al., 2008). Co-calibration refers to combining test scores across studies into a single metric. Briefly, we co-calibrated ADNI-MEM and ADNI-EF scores with NACC item level data to obtain NACC memory (NACC-MEM) and executive function (NACC-EF) scores on the same metric as ADNI using previously published methods (Paul K Crane et al., 2008; Mez et al., Under Review). Common memory measures in NACC and ADNI (i.e., Logical Memory Immediate and Delayed Recall) and common executive function measures (i.e., Digit Span Backwards, Verbal Fluency, Vegetable Fluency, and Trail Making Test Parts A and B) served as anchors for co-calibration. We calculated the memory and executive function scores for all NACC participants using parameters from ADNI-Mem and ADNI-EF. We performed co-calibration using Mplus software (Muthén & Muthén, 1998).

2.5 Quantification of Hippocampal Volume and Hippocampal Atrophy

The ADNI neuroimaging protocol has been reported in detail elsewhere (Jack et al., 2008). Images for the current study included original uncorrected 1.5T T1-weighted high-resolution three-dimensional structural data. Cortical reconstruction and volumetric segmentation were performed with the FreeSurfer image analysis suite version 4.3 in ADNI-1 and 5.1 in ADNI 2 (http://surfer.nmr.mgh.harvard.edu/) (Dale et al., 1999; Fischl, Sereno, & Dale, 1999;

Fischl, Sereno, Tootell, et al., 1999). FreeSurfer processing in ADNI has been described in detail elsewhere (Mormino et al., 2009). An early version of the longitudinal image processing framework was used to process the sequential scans (Reuter et al., 2012). We used left hippocampal volume as our primary outcome measurement and included a measurement of intracranial volume (ICV) as a covariate in all volumetric analyses, both of which were defined in FreeSurfer (Desikan et al., 2006). Mixed model regression, described below, was used to model annual change in brain volume. Neuroimaging data are not available in the NACC dataset.

2.6 Statistical Analyses

All statistical analyses were performed in R (version 2.15.2; http://www.r-project.org/). Our threshold for statistical significance was set *a priori* at $\alpha<0.05$. In all analyses, covariates consisted of age, sex, education, diagnostic status (normal cognition (NC), MCI, and AD), and ICV (when applicable). Cross-sectional analyses were performed using baseline data within a general linear model (R command glm). Longitudinal analyses were performed using a mixed-effects regression model (R package nlme, R command lme) with time modeled as years from baseline for each participant (days from baseline/365.25). Main effects of each CSF biomarker and the FSRP were performed first using separate models to establish associations between our variables of interest and selected phenotypes. Demographic characteristics were compared across diagnoses using one-way ANOVA, and post-hoc paired comparisons were performed using an independent samples t-test correcting for multiple comparisons.

2.6.1 FSRP x CSF Biomarker Levels on Hippocampal Volume—The baseline hippocampal volume model included a term for the CSF biomarker of interest (one model for Aβ-42, one model for total tau (t-tau), and one model for phosphorylated tau (p-tau)), a term for FSRP score, and a biomarker x FSRP interaction term. The longitudinal hippocampal volume model included identical terms but also included a 3-way biomarker x FSRP x time interaction term (with all lower order terms included) to evaluate the interaction effects on change in hippocampal volume over the follow-up period.

Post-hoc analyses evaluating 3-way diagnosis x FSRP x CSF biomarker interactions were run at baseline and longitudinally to assess whether the observed interaction effects differed between diagnostic categories. Additional sub-analyses were run evaluating interactions in relation to each neuropsychological test that went into our composite measures of cognition, and evaluating both Aβ-42 and t-tau in the same statistical model.

2.6.2 FSRP x CSF Biomarker Levels on Cognitive Performance—The baseline and longitudinal cognitive models included the same interaction and adjusting covariate terms listed above. One model was run with memory performance (ADNI-MEM) set as the outcome, and one model was run with executive function performance (ADNI-EF) set as the outcome. The same post-hoc tests above were run.

2.6.3 NACC Replication: FSRP x Autopsy Measures of AD Pathology on Cognitive Performance—In NACC, because we did not have baseline biomarker data,

we evaluated the FSRP x neuropathology interactions in two ways to best approximate the models tested in ADNI. First, we used a cross-sectional model leveraging cognitive data from the final visit prior to death to replicate the cross-sectional study in the initial analyses. Second, we used a longitudinal model leveraging all cognitive data points to evaluate trajectories of cognitive performance prior to death. In the longitudinal model time was modeled as years from death. The model also included age at final visit, sex, diagnosis at final visit, and education. Composite measures of cognition (NACC-EF and NACC-MEM) were set as quantitative outcomes in each statistical model.

3. Results

Demographic data are presented in Table 1. In ADNI, AD participants differed as expected compared to participants with normal cognition (NC) including a lower percentage of females, lower education levels, enhanced AD biomarker levels, lower cognitive performance levels, and smaller hippocampal volumes. In ADNI, stroke risk score was lowest in MCI participants but did not differ between AD and NC. In NACC, the AD participants had a lower percentage of females and showed lower cognitive performance levels than NC and MCI participants, but AD and MCI participants tended to be younger than NC participants. NC participants also tended to have slightly higher FSRP than MCI or AD.

3.1 Main Effects of FSRP and AD Biomarkers

At baseline, CSF Aβ-42 ($t(1115)=5.65$, $p<0.001$) and CSF t-tau ($t(1080)=-4.38$, $p<0.001$) were associated with hippocampal volume, while FSRP ($p=0.084$) and p-tau were not associated ($p=0.278$). CSF Aβ-42 ($t(1236)=8.48$, $p<0.001$), CSF t-tau ($t(1201)=-3.82$, $p<0.001$), CSF p-tau ($t(1232)=-4.92$, $p<0.001$), and FSRP ($t(1716)=-2.21$, $p=0.03$) were associated with baseline memory performance. Similarly, CSF Aβ-42 ($t(1236)=7.15$, $p<0.001$), CSF t-tau ($t(1201)=-6.53$, $p<0.001$), CSF p-tau ($t(1232)=-2.74$, $p=0.006$), and FSRP ($t(1716)=-4.43$, $p<0.001$) were all associated with baseline executive function performance.

When evaluating longitudinal change, CSF Aβ-42 ($t(2614)=9.34$, $p<0.001$), CSF t-tau ($t(2544)=-8.28$, $p<0.001$), and CSF p-tau ($t(2609)=-8.44$, $p<0.001$) were associated with hippocampal atrophy, while FSRP was not ($p=0.83$). All variables of interest were associated with faster memory decline, including CSF Aβ-42 ($t(6535)=11.43$, $p<0.001$), CSF t-tau ($t(1201)=-10.57$, $p<0.001$), CSF p-tau ($t(6508)=-6.64$, $p<0.001$), and FSRP ($t(10628)=-2.31$, $p=0.021$). Additionally, Aβ-42 ($t(6499)=11.60$, $p<0.001$), t-tau ($t(6416)=-9.79$, $p<0.001$), and p-tau ($t(6472)=-7.30$, $p<0.001$) were associated with faster decline in executive function, but FSRP showed no association ($p=0.90$).

3.2 Interaction between FSRP and AD Biomarkers on Hippocampal Volume

In baseline analyses, there was a significant interaction between FSRP and Aβ-42 ($t(1108)=-2.81$, $p=0.005$) on hippocampal volume in which the relation between stroke risk and smaller hippocampal volume was strongest in individuals with lower brain amyloid burden (higher CSF Aβ-42 levels; Figure 1). It should be noted that lower CSF Aβ-42 is indicative

of higher brain amyloid burden (Jagust et al., 2009). In longitudinal analyses, there were no significant interactions. Results are presented in Table 2.

3.3 Interaction between FSRP and AD Biomarkers on Cognition

In baseline analyses, there was a significant interaction effect between FSRP and Aβ-42 ($t(1229)=-2.95$, $p=0.003$) on memory performance whereby the relation between stroke risk and worse cognitive performance was strongest in the presence of lower brain amyloid burden (higher CSF Aβ-42 levels; Figure 1). However, the worst performance was observed in those with both biomarker positivity and high stroke risk (Figure 2). There was also a significant FSRP x Aβ-42 x diagnosis interaction ($t(1223)=-2.06$, $p=0.024$) by which the interaction between stroke risk and Aβ-42 was strongest in MCI participants. There were no significant interactions in relation to baseline executive function.

In longitudinal analyses, there was a significant interaction between FSRP x t-tau x interval ($t(6436)=2.38$, $p=0.017$), and FSRP x p-tau x interval ($t(6493)=2.08$, $p=0.038$) on longitudinal memory performance. In both cases, the relation between stroke risk and worsening cognition was strongest in biomarker negative individuals (those with lower CSF t-tau and p-tau). There was also a significant interaction between FSRP x Aβ-42 x interval ($t(6484)=-2.32$, $p=0.02$) on executive function performance and between FSRP x t-tau x interval ($t(6401)=2.18$, $p=0.03$) on executive function performance. There were no significant diagnostic interactions. Results are presented in Table 2. Secondary sub-analyses across each of the neuropsychological tests that went into the composite measures of cognition are presented in Supplementary Table 1. Secondary analyses evaluating Aβ-42 and t-tau in the same statistical model are presented in Supplementary Table 2.

3.4 NACC Replication of FSRP x Biomarker Interaction on Neuropsychological Performance using Autopsy Measures of Pathology

Replication results are presented in Table 2. FSRP was not cross-sectionally or longitudinally related to memory or executive function performance in NACC. However, we did observe a significant FSRP x diagnosis interaction in relation to executive function performance prior to death ($F(2,1113)=13.56$, $p<0.001$) with a strong main effect of FSRP in individuals with normal cognition, a weaker effect in MCI, and no effect in individuals with AD.

In cross-sectional replication analyses leveraging cognitive data from the last visit before death, FSRP interacted with amyloid positivity on memory performance ($t(1113) = 2.21$, $p=0.027$) and executive function ($t(1113) = 1.98$, $p=0.048$), and interacted with tau positivity on executive function ($t(1113) = 2.27$, $p=0.024$). The FSRP effect was again strongest in tau negative participants and amyloid negative participants, replicating the ADNI finding (Figure 3). There were no three-way interactions among pathology, diagnosis, and FSRP.

In longitudinal replication analyses, FSRP did not interact with amyloid positivity or tau positivity in relation to trajectories of memory or executive function performance (p-values>0.11). There were no diagnostic interactions present.

4. Discussion

This paper sought to identify and describe interactions between stroke risk factors and AD biomarkers in conferring risk for neurodegeneration and cognitive impairment. Our results suggest that there may be a dynamic interplay between the AD pathological cascade and vascular health whereby the level of risk for brain aging associated with vascular risk factors depends in part on the presence or absence of AD pathology.

Stroke risk appears to be most related to brain aging in the absence of AD biomarkers. Although this explanation is somewhat counterintuitive, we observed the effect consistently across phenotypes in ADNI, and in the NACC replication sample. The stronger effect of vascular risk in biomarker negative versus positive participants is illustrated in Figure 1 and suggests that controlling stroke risk factors may be most important in individuals who are otherwise at low risk for AD. Some previous work leveraging neuropathologic measures of cerebrovascular disease and AD have demonstrated a comparable interaction whereby the effect of cerebrovascular disease was strongest in those participants without AD pathology (Chui et al., 2006). At the same time, we also observed a subtle additive effect at baseline in which the smallest baseline brain volumes and poorest cognitive performances were observed in individuals with high stroke risk and AD biomarker positivity (Figure 2). The additive effect of AD and stroke risk factors is consistent with previous autopsy findings suggesting an additive effect of cerebrovascular disease on cognition in the presence of AD pathology (Schneider, Boyle, et al., 2007). Recent work leveraging white matter hyperintensity and amyloid imaging data has shown a comparable additive effect of amyloid and white-matter hyperintensities on conversion to AD (Provenzano et al., 2013). Our findings therefore provide additional evidence that vascular risk and AD biomarkers are independently associated with cognitive impairment, and that each may provide a “hit” that ultimately contributes to the clinical manifestation of dementia.

Recent work by Villeneuve et al. (Villeneuve et al., 2014) leveraged a cohort with a wider range of cerebrovascular disease than the participants included here. Their findings suggest the association between stroke risk and parietal cortical thinning may be strongest in amyloid positive participants. We, too, observed some indication of an interactive effect whereby the most severe brain atrophy was observed in participants with both vascular risk and amyloid positivity (Figure 2), but our results do not support the conclusion that vascular risk is most predictive in biomarker positive individuals. Compared to the Villeneuve et al. study, our work included a broader representation of the cognitive aging spectrum and a more restricted range of vascular risk. Thus, it is possible that differences in sample characteristics could explain the disparate findings between prior work and current results. Additional methodological differences potentially underlying the discrepancy includes our evaluation of biomarker levels as a continuous variable in our interaction models, the inclusion of additional covariates (age, sex, education, and diagnosis), the focus on the hippocampus rather than the parietal cortex, the inclusion of more participants in our samples, and our assessment of both cross-sectional and longitudinal changes. Additional work in community and memory clinic referral samples is needed to better understand the dynamic interplay between vascular risk and AD biomarkers across the spectrum of cognitive aging and dementia.

Previous work in ADNI has suggested an independent contribution of cerebrovascular disease (operationalized using white-matter hyperintensities) and CSF-based AD biomarkers to cognitive impairment, however interactions were not assessed (Barnes et al., 2013). Moreover, white-matter hyperintensities have been associated with decreased glucose metabolism and decline in executive function in ADNI, but have shown no association with AD biomarker levels (Lo et al., 2012). Again, interactions were not evaluated. Future work focusing on the interactions between regional cerebrovascular disease (e.g., white-matter hyperintensities, cerebral infarcts), and regional AD biomarker load using PET imaging may clarify how vascular risk and injury interacts with AD biomarkers in conferring risk for cognitive decline.

It is interesting that AD biomarkers showed a stronger relation than stroke risk to all the brain aging outcomes (hippocampal volume, neuropsychological performance) in this analysis, likely due to a selection bias in the ADNI and NACC cohorts. The ADNI enrollment protocol excludes for overt cerebrovascular disease (Hachinski score<4), so the presence of stroke risk and cerebrovascular pathology is likely underrepresented in this population compared to community-based cohorts (Massoud et al., 1999). Despite this limitation, we still observed an association between stroke risk and baseline executive function, baseline memory performance, and longitudinal memory performance in ADNI. In all cases, higher stroke risk levels were associated with worse cognitive performance, consistent with previous findings (Brady et al., 2001; Jefferson et al., *In Press*; Seshadri et al., 2004). Even in a population with a greatly reduced spectrum of cerebrovascular disease, the contribution of adverse vascular health remains important to brain aging.

This manuscript has several strengths including the two independent samples that allowed us to extend the observed *in vivo* interactions between stroke risk and AD biomarkers to *ex vivo* interactions between vascular and AD pathologies. The inclusion of multiple brain aging phenotypes also allowed for the evaluation of stroke risk and AD biomarkers in the context of both cognition and neurodegeneration. However, this project is not without weaknesses. There may be a bias toward low levels of cerebrovascular disease in the ADNI sample that preclude generalizability to older adults in the population. Relatedly, we also observed smaller effects of vascular health on cognition and brain volume than would be expected from the literature (Elias et al., 2004).

In conclusion, this manuscript identified an interaction between stroke risk factors and AD biomarkers in which the effect of one is strongest in the absence of the other. Future work evaluating these factors in a representative population with more prevalent cerebrovascular disease is warranted to improve the generalizability of the observed interaction effects.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This research was supported in part by Pharmaceutical Research and Manufacturers of America Foundation Fellowship in Translational Medicine and Therapeutics (TJH), Alzheimer's Association IIRG-08-88733 (ALJ),

K24-AG046373 (ALJ), R01-AG034962 (ALJ), R01-HL111516 (ALJ), K12-HD043483 (TJH, KAG), R01 AG042437 (SM) and the Vanderbilt Memory & Alzheimer's Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; ; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Rev December 5, 2013 Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI David Teplow, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), and P50 AG005681 (PI John Morris, MD). The authors appreciate the help of Paul K. Crane, MD MPH and Laura E. Gibbons for providing item parameters for ADNI-Mem and ADNI-EF.

References

Barnes J, Carmichael OT, Leung KK, Schwarz C, Ridgway GR, Bartlett JW, Biessels GJ. Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. Neurobiology of Aging. 2013; 34(8):1996–2002. [PubMed: 23522844]

Beekly DL, Ramos EM, van Belle G, Deitrich W, Clark AD, Jacka ME, Kukull WA. The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database. Alzheimer Disease & Associated Disorders. 2004; 18(4):270–277. [PubMed: 15592144]

Brady CB, Spiro A, McGlinchey-Berroth R, Milberg W, Gaziano JM. Stroke Risk Predicts Verbal Fluency Decline in Healthy Older Men Evidence From the Normative Aging Study. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences. 2001; 56(6):340–346.

Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E, Hampel H. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology. 2005; 65(9):1502–1503. [PubMed: 16275849]

Buerger K, Ewers M, Pirttil T, Zinkowski R, Alafuzoff I, Teipel SJ, Soininen H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006; 129(11):3035–3041. [PubMed: 17012293]

Chui HC, Zarow C, Mack WJ, Ellis WG, Zheng L, Jagust WJ, DeCarli CC. Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Annals of neurology. 2006; 60(6):677–687. [PubMed: 17192928]

Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Harvey D. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging and Behavior. 2012; 6(4):502–516. [PubMed: 22782295]

Crane PK, Narasimhalu K, Gibbons LE, Mungas DM, Haneuse S, Larson EB, van Belle G. Item response theory facilitated cocalibrating cognitive tests and reduced bias in estimated rates of decline. Journal of Clinical Epidemiology. 2008; 61(10):1018–1027. [PubMed: 18455909]

D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994; 25(1):40–43. [PubMed: 8266381]

Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis: I. Segmentation and surface reconstruction. Neuroimage. 1999; 9(2):179–194. [PubMed: 9931268]

de Souza LC, Chupin M, Lamari F, Jardel C, Leclercq D, Colliot O, Sarazin M. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiology of Aging. 2012; 33(7): 1253–1257. [PubMed: 21489655]

Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Hyman BT. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006; 31(3):968–980. [PubMed: 16530430]

Diaz-Ruiz C, Wang J, Ksiezak-Reding H, Ho L, Qian X, Humala N, Pasinetti G. Role of Hypertension in Aggravating Aβ Neuropathology of AD Type and Tau-Mediated Motor Impairment. Cardiovascular psychiatry and neurology. 2009:1–9. 2009.

Elias MF, Sullivan LM, D'Agostino RB, Elias PK, Beiser A, Au R, Wolf PA. Framingham stroke risk profile and lowered cognitive performance. Stroke. 2004; 35(2):404–409. [PubMed: 14726556]

Fischl B, Sereno MI, Dale AM. Cortical Surface-Based Analysis: II: Inflation, Flattening, and a Surface-Based Coordinate System. Neuroimage. 1999; 9(2):195–207. [PubMed: 9931269]

Fischl B, Sereno MI, Tootell RBH, Dale AM. High-resolution intersubject averaging and a coordinate system for the cortical surface. Human brain mapping. 1999; 8(4):272–284. [PubMed: 10619420]

Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Dale AM. Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cerebral Cortex. 2010; 20(9): 2069–2079. [PubMed: 20051356]

Gentile MT, Poulet R, Pardo AD, Cifelli G, Maffei A, Vecchione C, Lembo G. β-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiology of Aging. 2009; 30(2):222–228. [PubMed: 17673335]

Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, Crane PK. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging and Behavior. 2012; 6(4): 517–527. [PubMed: 22644789]

Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Ward C. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. Journal of Magnetic Resonance Imaging. 2008; 27(4):685–691. [PubMed: 18302232]

Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology. 2013; 12(2):207–216. [PubMed: 23332364]

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet Neurology. 2010; 9(1):119. [PubMed: 20083042]

Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Price JC. Relationships between biomarkers in aging and dementia. Neurology. 2009; 73(15):1193–1199. [PubMed: 19822868]

Jefferson, AL.; Hohman, TJ.; Liu, D.; Haj-Hassan, S.; Gifford, KA.; Benson, EM.; Ruberg, FL. Journal of Alzheimer's Disease. Adverse Vascular Risk is Related to Cognitive Decline in Older Adults. In Press

Kivipelto M, Laakso MP, Tuomilehto J, Nissinen A, Soininen H. Hypertension and Hypercholesterolaemia as Risk Factors for Alzheimer's Disease. CNS drugs. 2002; 16(7):435–444. [PubMed: 12056919]

Lo RY, Jagust WJ, Weiner M, Aisen P, Petersen R, Jack CR, Beckett L. Vascular burden and Alzheimer disease pathologic progression. Neurology. 2012; 79(13):1349–1355. [PubMed: 22972646]

Massoud F, Devi G, Stern Y, Lawton A, Goldman JE, Liu Y, Mayeux R. A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia. Archives of neurology. 1999; 56(11):1368–1373. [PubMed: 10555657]

Mez, J.; Mukherjee, S.; Thornton, T.; Fardo, D.; Trittschuh, E.; Sutti, S.; Crane, PK. Prominent executive dysfunction in Alzheimer's disease is highly heritable. Under Review

Moreno-Gonzalez I, Estrada LD, Sanchez-Mejias E, Soto C. Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. Nature communications. 2013; 4:1495.

Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Jagust WJ. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009; 132(5):1310–1323. [PubMed: 19042931]

Muthén LK, Muthén BO. Mplus. Statistical analyses with latent variables. User's guide. 1998; 3

Provenzano FA, Muraskin J, Tosto G, et al. White matter hyperintensities and cerebral amyloidosis: Necessary and sufficient for clinical expression of alzheimer disease? JAMA Neurology. 2013; 70(4):455–461. doi: 10.1001/jamaneurol.2013.1321. [PubMed: 23420027]

Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage. 2012; 61(4):1402–1418. [PubMed: 22430496]

Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007; 69(24):2197–2204. [PubMed: 17568013]

Schneider JA, Bennett DA. Where vascular meets neurodegenerative disease. Stroke. 2010; 41(10 suppl 1):S144–S146. [PubMed: 20876491]

Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Annals of neurology. 2007; 62(1):59–66. [PubMed: 17503514]

Seshadri S, Wolf P, Beiser A, Elias M, Au R, Kase C, DeCarli C. Stroke risk profile, brain volume, and cognitive function The Framingham Offspring Study. Neurology. 2004; 63(9):1591–1599. [PubMed: 15534241]

Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Dean RA. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathologica. 2011; 121(5):597–609. [PubMed: 21311900]

Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Annals of neurology. 2008; 64(2):168–176. [PubMed: 18496870]

Villeneuve S, Reed BR, Madison CM, Wirth M, Marchant NL, Kriger S, Chui HC. Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions. Neurology. 2014; 83(1): 40–47. [PubMed: 24907234]

Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick W, Bowen JD, Li G. Blood Pressure and Brain Injury in Older Adults: Findings from a Community-Based Autopsy Study. Journal of the American Geriatrics Society. 2009; 57(11):1975–1981. [PubMed: 19793158]

Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991; 22(3):312–318. [PubMed: 2003301]

Highlights

- We evaluate the interaction between Alzheimer's biomarkers and stroke risk factors
- We extend the interaction results to autopsy measures of AD pathology
- Stroke risk strongly predicts cognitive decline in the absence of AD biomarkers
- Stroke risk strongly predicts cognitive decline in the absence of AD pathology
- Stroke risk and AD pathology likely relate to cognition through independent pathways



Figure 1. CSF Aβ-42 Interacts with Stroke Risk on Brain Aging

FSRP is along the x axis and Aβ-42 groups are split based on a previously identified cut point (Aβ-42 positive ≤ 192). In row **A**, baseline left hippocampal volume is along the y axis. In row **B**, baseline memory performance is along the y axis. In row **C**, annual change in memory performance is along the y axis.



Figure 2. The Presence of High Stroke risk and AD Biomarker Positivity is related to Low Hippocampal Volumes and Memory Performance Scores at Baseline

CSFAβ-42 group is along the x axis and groups are separated based on a median split of the FSRP score. Error bars represent the 95% confidence intervals. In panel **A**, baseline hippocampal volume is along the y axis. In panel **B**, baseline memory performance is along the y axis.



Figure 3. Fitted Plots Demonstrating Interaction between FSRP and Amyloid on Memory Performance in ADNI and NACC

Graphs illustrate the predicted trajectories from the full regression model correcting for age, sex, education, and diagnosis. Fitted models are for a male participant of average age and average education level with MCI. FSRP is along the x axis. In panel **A**, annual change in composite memory performance is along the Y-axis and groups are defined based on CSF CSFAβ-42 levels (Aβ-42 positive ≤ 192). In panel **B**, composite memory performance at last visit is along the Y-axis and groups are defined based on CERAD neuritic plaque score in which no or sparse plaques are considered Amyloid Negative and moderate or frequent plaques are considered Amyloid Positive. Shaded regions represent the 95% confidence interval for the regression line.

Table 1

Sample Characteristics

ADNI: Brain Volume Dataset	Baseline Clinical Diagnosis[#]			F-Test
	Normal Control	Mild Cognitive Impairment	Alzheimer's Disease	
Sample Size, n	342	558	182	n/a
APOE ε4 Carriers, %	27%	49%	68%	n/a
Females, %	53%	41%	46%	n/a
Baseline Age, years	74±6	72±7	74±8	F(2,1079)=7.31, p<0.001
Education, years	16±3	16±3	15±3	F(2,1079)=6.33, p=0.002
Visits, total	3±2	4±2	2±1	F(2,1079)=38.64, p<0.001
Stroke Risk Profile Score	13±4	12±4	13±5	F(2,1079)=4.79, p=0.009
CSF Total Tau, pg/mL	67±30	91±56	131±62	F(2,1079)=94.59, p< 0.001
CSF P-Tau, pg/mL	32±19	39±22	52±29	F(2,1074)=47.14, p< 0.001
CSF Aβ-42, pg/mL,	200±52	172±53	140±41	F(2,1079)=84.82, p< 0.001
Left Hippocampal Volume	3698±436	3360±604	2883±540	F(2,1079)=133.99, p< 0.001
ADNI: Cognition Dataset				
Sample Size, n	369	607	226	n/a
APOE ε4 Carriers, %	27%	49%	67%	n/a
Females, %	53%	41%	42%	n/a
Baseline Age, years	74±6	73±8	75±8	F(2,1199)=8.98, p<0.001
Education, years	16±3	16±3	15±3	F(2,1199)=8.08, p<0.001
Visits, total	7±8	7±7	3±1	F(2,1199)=32.41, p<0.001
Stroke Risk Profile Score	13±4	12±4	13±4	F(2,1199)=5.11, p=0.006
CSF Total Tau, pg/mL	68±32	91±56	127±62	F(2,1199)=96.24, p<0.001
CSF P-Tau, pg/mL	32±19	39±22	51±30	F(2,1194)=48.46, p<0.001
CSF Aβ-42, pg/mL,	200±52	172±53	140±39	F(2,1199)=99.38, p<0.001
Episodic Memory	0.94±0.51	0.19±0.592	−0.71±0.513	F(2,1199)=626.92, p<0.001
Executive Function	0.78±0.72	0.21±0.798	−0.83±0.82	F(2,1199)=297, p<0.001
NACC: Cognition Replication Dataset				
Sample Size, n	240	110	772	n/a
APOE ε4 Carriers, %	14%	24%	44%	n/a
Females, %	62%	46%	45%	n/a
Age at Death, years	86±9	83±9	83±9	F(2,1119)=9.01, p<0.001
Education, years	15±3	15±3	15±3	F(2,1119)=2.17, p=0.114
Visits, total	2.84±1.55	2.07±1.276	2.66±1.493	F(2,1119)=10.19, p<0.001
Time to Death, years	1.47±1.13	2.06±1.544	1.82±1.377	F(2,1119)=8.92, p<0.001
Stroke Risk Profile Score	16±4	15±5	15±4	F(2,1119)=11.03, p<0.001
Episodic Memory	0.17±0.165	0±0.197	−0.26±0.177	F(2,1119)=579.53, p<0.001
Executive Function	0.08±0.736	−0.74±0.8	−1.52±0.903	F(2,1119)=325.26, p<0.001

[#]Diaqnostic qroups were defined accordinq to the ADNI protocol. Normal Control participants had a Mini-Mental Status Examination (MMSE) score between 24 and 30, a Clinical Dementia Rating (CDR) score of 0, and were not depressed (Geriatric Depression Scale score <6). Mild Cognitive Impairment participants had a MMSE score between 24 and 30, objective memorv impairment, subjective memory impairment, and a CDR score of 0.5. Alzheimer's Disease participants met clinical criteria for dementia, had an MMSE of between 20 and 26, and had CDR score of . 5 or 1.

Table 2

Associations Between FSRP and Brain Aging Variables

	FSRP		FSRP x Aβ-42		FSRP x Tau		FSRP x PTau	
Baseline Outcomes	**β**	**p-value**	**β**	**p-value**	**β**	**p-value**	**β**	**p-value**
Hippocampal Volume	−7.02	0.084	**−0.19**	**0.005**	−0.02	0.753	0.04	0.775
Episodic Memory Composite	**−0.01**	**0.027**	**−0.0002**	**0.0004**	**0.0001**	**0.035**	**0.0004**	**0.006**
Executive Function Composite	**−0.028**	**3.19×10^{-6}**	−0.0002	0.085	0.00008	0.402	0.0003	0.256
Longitudinal Outcomes	**β**	**p-value**	**β**	**p-value**	**β**	**p-value**	**β**	**p-value**
Hippocampal Volume	−0.132	0.823	−0.005	0.719	0.026	0.060	−0.005	0.885
Episodic Memory Composite	**−0.003**	**0.021**	−0.00005	0.098	**0.00007**	**0.017**	**0.0002**	**0.038**
Executive Function Composite	0.0002	0.896	**−0.00009**	**0.020**	**0.00009**	**0.030**	0.0002	0.072

NACC Replication: Autopsy Sample	**FSRP**		**FSRP x Amyloid Positivity**		**FSRP x Tau Positivity**	
Last Visit Prior to Death Outcomes	**β**	**p-value**	**β**	**p-value**	**β**	**p-value**
Episodic Memory Composite	−0.0008	0.538	**0.005**	**0.027**	−0.00002	0.991
Executive Function Composite	0.0003	0.970	**0.022**	**0.048**	**0.025**	**0.024**
Longitudinal Outcomes	**β**	**p-value**	**β**	**p-value**	**β**	**p-value**
Episodic Memory Composite	−0.0007	0.083	−0.00003	0.972	0.001	0.115
Executive Function Composite	−0.003	0.112	0.005	0.202	−0.003	0.362

Boldface signifies effects that are significant at $p < 0.05$.